The Technical Analyst
EyePoint Pharmaceuticals [EYPT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
EyePoint Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-6.26% $16.47
America/New_York / 24 apr 2024 @ 13:40
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 820.71 mill |
| EPS: | -1.820 |
| P/E: | -9.05 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 49.83 mill |
| Avg Daily Volume: | 0.987 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.05 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.54x |
| Company: PE -9.05 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-12.07 (-173.26%) $-28.54 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 14.93 - 17.69 ( +/- 8.48%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Adage Capital Management, L.p. | Buy | 0 | Common Stock, par value $0.001 per share ("Common Stock") |
| 2024-04-18 | Cormorant Asset Management, Lp | Buy | 186 521 | Common Stock |
| 2024-04-18 | Cormorant Asset Management, Lp | Buy | 395 244 | Common Stock |
| 2024-03-30 | Paggiarino Dario A. | Buy | 14 000 | Common Stock |
| 2024-03-30 | Paggiarino Dario A. | Buy | 30 570 | Common Stock |
| INSIDER POWER |
|---|
| 41.03 |
| Last 98 transactions |
| Buy: 1 049 923 | Sell: 467 144 |
Forecast:
15:19 - $16.34
Live Trading Signals (every 1 min)
Forecast
1: 13:49 - $16.45
Forecast 2: 14:39 - $16.31
Forecast 3: 15:19 - $16.34
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.47 (-6.26% ) |
| Volume | 0.470 mill |
| Avg. Vol. | 0.987 mill |
| % of Avg. Vol | 47.66 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EYPT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $29.68 | N/A | Active |
|---|
EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Latest Press Releases
2024-04-16 07:00:00 - Press Release
Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Watertown, mass., april 16, 2024 (globe newswire) -- eyepoint pharmaceuticals, inc. (nasdaq: eypt), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the company granted non-statutory stock options to new employees as inducement awards outside the company's 2023 long-term incentive plan in accordance with nasdaq listing rule 5635(c)(4).
2024-04-02 07:00:00 - Press Release
Eyepoint Pharmaceuticals Expands Scientific Advisory Board With World-renowned Retina Specialists
- charles wykoff, m.d., ph.d. joins carl regillo, m.d.
2024-03-18 07:00:00 - Press Release
Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Watertown, mass., march 18, 2024 (globe newswire) -- eyepoint pharmaceuticals, inc. (nasdaq: eypt), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the company granted non-statutory stock options to new employees as inducement awards outside the company's 2023 long-term incentive plan in accordance with nasdaq listing rule 5635(c)(4).
2024-03-07 07:00:00 - Press Release
Eyepoint Pharmaceuticals Reports Fourth Quarter And Full-year 2023 Financial Results And Highlights Recent Corporate Developments
– announced positive topline efficacy and safety data from the phase 2 davio 2 trial of eyp-1901 in wet amd achieving all primary and secondary endpoints; initiation of the first phase 3 clinical trial expected in 2h 2024 –
2024-03-04 07:00:00 - Press Release
Eyepoint Pharmaceuticals Announces Appointment Of Ramiro Ribeiro, M.d., Ph.d. As Chief Medical Officer
– company on-track to report topline data in 2q 2024 for the phase 2 pavia clinical trial of eyp-1901 in moderately severe-to-severe npdr –
Latest News
2024-03-07 10:31:18 - Zacks Investment Research
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for EyePoint Pharmaceuticals (EYPT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
2024-02-29 11:01:05 - Zacks Investment Research
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-29 09:51:08 - Zacks Investment Research
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
EyePoint Pharmaceuticals (EYPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2024-02-29 07:00:00 - GlobeNewsWire
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 7, 2024 to report its fourth quarter and full-year 2023 financial results and highlight recent corporate developments.
2024-02-27 07:00:00 - GlobeNewsWire
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that Company management will participate at the following upcoming conferences:
2024-02-21 08:36:08 - Seeking Alpha
EyePoint Is Betting The Bank On EYP-1901
EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care. The company has a strong drug delivery platform with Durasert and has sold off its profitable YUTIQ business. EYP-1901 targets multi-billion dollar markets in wet AMD, NPDR, and DME, but it's not entirely a slam dunk as competition is increasing.
2024-02-15 13:00:20 - Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-02-13 10:56:05 - Zacks Investment Research
Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet
The consensus price target hints at a 31.3% upside potential for EyePoint Pharmaceuticals (EYPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-01-31 07:00:00 - GlobeNewsWire
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that George Elston, Executive Vice President and Chief Financial Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 p.m. ET.
2023-12-20 07:00:00 - GlobeNewsWire
EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 10:30 a.m. PT/1:30 p.m. ET.